ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

etrasimod

Also written as “Etrasimod”, “APD334” and “Etrasimod Immediate Release (IR)”.

Its studies are mostly in Colitis, Ulcerative · Dermatitis, Atopic · Crohn Disease · Alopecia Areata · Eosinophilic Esophagitis, led by 2 companies.

Drug pageEtrasimod: every studyAll 23 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since May 8, 201921 company-led studies, 4 open or runningNext primary completion: Jun 16, 2029 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizerits history only203 open or runningphase 3since May 8, 2019May 13, 2015Jun 16, 2029phase 2 · NCT05287126
Everstar Therapeutics11 open or runningphase 3since Nov 22, 2019Nov 22, 2019none ahead

Also a collaborator on its studies: Arena is a wholly owned subsidiary of Pfizer.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Everstar Therapeutics only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Dec 9, 2016Named etrasimodINNProposed as its International Nonproprietary Name in WHO's List 116 · before, APD334
  2. Nov 22, 2019First study: phase 3 study in Moderately to Severely Active Ulcerative ColitisFirst studyNCT04176588 · 341 enrolled · China

TargetBeta

“Sphingosine 1-phosphate receptor Edg-1 agonist; Sphingosine 1-phosphate receptor Edg-6 modulator; Sphingosine 1-phosphate receptor Edg-1 modulator; Sphingosine 1-phosphate receptor Edg-8 modulator”ChEMBL 37, by rule

Other programs on the same three targets

ProgramCompanyFurthest phaseStudies
fingolimodruleNovartisphase 455

Studies

The one study Everstar Therapeutics leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04176588Moderately to Severely Active Ulcerative Colitis · China3Active, not recruitingJul 2024341

How it is read

Names in the registry

  • “Etrasimod”, 19 entries
  • “APD334”, 3 entries
  • “etrasimod”, 1 entry
  • “Etrasimod Immediate Release (IR)”, 1 entry
  • “Etrasimod 1 mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.